Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database

Compound ILABs had significant CAE risk signals, especially those of atrial fibrillation, myocardial infarction and heart failure, and the risk signal was stronger in the early stage of drug treatment. Except for a few individual adverse events, the overall CAE risk signal associated with triple inhaled agents (mainly Fluticasone/umeclidinium/vilanterol) was comparable to that of dual bronchodilators.